Plasma-Derived Therapies Market Trends and Forecast
The future of the global plasma-derived therapies market looks promising with opportunities in the hospital and retail pharmacy markets. The global plasma-derived therapies market is expected to grow with a CAGR of 6.5% from 2025 to 2031. The major drivers for this market are rising prevalence of chronic diseases, advancements in plasma collection and processing technologies, and growing awareness and acceptance of plasma-based treatments.
• Lucintel forecasts that, within the type category, immune globulin is expected to witness the highest growth over the forecast period due to its widespread use in treating immune deficiencies.
• Within the application category, hospital is expected to witness the highest growth due to their handling of a larger volume of specialized medications for acute and critical conditions.
• In terms of region, North America is expected to witness the highest growth over the forecast period due to high demand for plasma therapies.
Emerging Trends in the Plasma-Derived Therapies Market
There are many emerging trends in the Plasma-derived Therapies Market, triggered by new technological developments and regulatory mechanisms that have been implemented to modify changing patient needs. These trends are changing the market structure by modifying both the production and consumption of plasma-derived products in the world.
• Precision Medicine and Tailored Therapies: Precision medicine, which is increasingly based on genetic and molecular information to create individualized treatment plans, is influencing the Plasma-derived Therapies Market. Advances in genetic research are allowing for the development of therapies that are tailored to specific patient needs, improving the effectiveness of treatments for conditions such as autoimmune diseases and bleeding disorders. This shift is driving demand for more targeted plasma-derived therapies, including specialized immunoglobulins and clotting factors that address specific genetic markers.
• Expanding Applications Beyond Traditional Uses: Scope Plasma-derived therapies continue to be an area of new applications beyond classical uses, for example, immunodeficiency or bleeding disorders. Researchers are interested in using the plasma-derived product for chronic disease conditions, for example, liver disease, neurodegenerative diseases, or certain cancers, and so the scope of indications is growing day by day with the progress in clinical trials that are conducted and the market becomes more and more promising.
• Rising Demand for Plasma Collection and Processing Technology: With the growing demand for plasma-derived therapies, there has been significant investment in improving plasma collection and processing technologies. Companies are developing more efficient and automated systems for collecting and processing plasma, which help increase plasma yield, reduce contamination risks, and improve overall product quality. These advancements are enabling manufacturers to meet the rising demand for plasma products while ensuring the safety and purity of the therapies.
• Expansion in Emerging Markets: The Plasma-derived Therapies Market is seeing significant growth in emerging markets such as China, India, and Latin America. In these regions, the demand for plasma-derived therapies is increasing due to the rising prevalence of chronic diseases, improving healthcare infrastructure, and greater patient awareness. Pharmaceutical companies are expanding their production and distribution networks to meet the growing demand in these markets, offering a significant growth opportunity for plasma-derived products.
• Regulatory Advances and Global Harmonization: The growth of the Plasma-derived Therapies Market is highly associated with regulatory development. The aim is to have a harmonized regulation in the regions so that the approval of plasma-derived products becomes more straightforward. The regulatory bodies, FDA and EMA, are upgrading guidelines for supporting the development of new therapies in line with stringent safety standards. Manufacturers will then be able to take advantage of less complexity while dealing with the international market through standardized regulatory procedures.
These emerging trends are reshaping the Plasma-derived Therapies Market, driving growth in new therapeutic areas, improving production capabilities, and expanding the marketÄX%$%Xs global reach. As precision medicine, new applications, and regulatory advancements continue to evolve, the plasma-derived therapies sector will become an even more crucial component of global healthcare.
Recent Development in the Plasma-Derived Therapies Market
The Plasma-derived Therapies Market has been undergoing rapid development in recent years, driven by technological innovations, increasing demand for specialized therapies, and expanding production capabilities. The following are five key developments that are significantly impacting the market.
• Technological Advancements in Plasma Processing: Technological innovations in plasma collection and processing are one of the key drivers of the Plasma-derived Therapies Market. New automated systems are being implemented to improve the efficiency and safety of plasma collection, while advancements in purification technologies are enhancing the quality of plasma-derived products. These improvements are making it possible to meet the rising global demand for immunoglobulins, clotting factors, and other plasma-based treatments.
• Expansion of Plasma Collection Networks: To meet the growing demand for plasma-derived therapies, many countries are expanding their plasma collection networks. New collection centers are being established globally, particularly in regions with underdeveloped plasma infrastructure. This expansion is crucial for ensuring a steady supply of high-quality plasma, which is essential for the production of therapies. Efforts to increase plasma donation rates are also helping to address shortages and ensure sustainability in plasma supply.
• Research into New Plasma-derived Therapeutics: Research into new plasma-derived therapeutics is gaining momentum, with studies exploring their potential use in treating conditions such as neurodegenerative diseases, cancer, and chronic liver disease. Ongoing clinical trials are testing the efficacy of these therapies, and early results are promising. These developments offer a significant opportunity to expand the use of plasma-derived therapies into new areas of medicine, potentially leading to market diversification.
• Regulatory Changes and Market Approvals: Regulatory changes are facilitating the approval of new plasma-derived therapies, enabling quicker access to life-saving treatments. Agencies like the FDA and EMA have streamlined approval processes, providing clearer guidelines for manufacturers to follow. This has accelerated the commercialization of novel plasma-based therapies, benefiting patients in need of new treatment options. As regulatory standards become more aligned, global access to these therapies will increase.
• Partnerships and Collaborations in the Plasma Industry: Partnerships between pharmaceutical companies, research institutions, and plasma collection centers are fostering innovation in the plasma-derived therapies market. These collaborations are essential for sharing expertise, increasing production capacity, and expanding global distribution networks. Strategic partnerships are enabling companies to address challenges such as plasma shortages and regulatory hurdles while improving access to these life-saving therapies.
The advancements in plasma-derived therapies are significantly increasing the market growth rate with innovative developments in technology, regulatory framework, and therapeutic applications.
Strategic Growth Opportunities in the Plasma-Derived Therapies Market
The Plasma-derived Therapies Market presents several strategic growth opportunities across key applications, including immune disorders, bleeding disorders, and chronic diseases. These growth areas are driven by technological innovations, regulatory changes, and expanding global demand for plasma-derived products.
• Expansion in Immune Disorder Treatments: The increasing prevalence of immune disorders such as PIDD is thereby one of the factors that pose great growth opportunity in plasma-derived therapies. Among other plasma-derived products, immunoglobulins hold a crucial market share because it is mainly applied for treatment against these immune disorders. A wide awareness and healthcare access improvement throughout the globe tend to propel rapid growth for immunoglobulin therapy markets and this offers robust growth potential.
• Bleeding Disorder Therapeutics: Bleeding disorders, particularly hemophilia, represent a critical application for plasma-derived therapies. The demand for clotting factor concentrates is increasing as more patients are diagnosed with bleeding disorders. Advances in clotting factor therapies, such as extended half-life products, are improving treatment outcomes and providing a strong growth opportunity. As global healthcare systems improve, the market for bleeding disorder therapeutics will continue to expand, especially in emerging markets.
• Chronic Disease Applications: Chronic diseases such as liver disease, neurodegenerative disorders, and cardiovascular conditions are creating new growth opportunities for plasma-derived therapies. Researchers are exploring the use of plasma products for these conditions, and clinical trials are underway to assess their efficacy. As new therapeutic applications are discovered, the market for plasma-derived therapies is diversifying, offering new growth opportunities in the treatment of chronic diseases.
• Emerging Markets for Plasma-derived Therapies: Emerging markets, particularly in Asia-Pacific, Latin America, and Africa, present significant growth opportunities for plasma-derived therapies. As healthcare infrastructure improves and awareness of plasma-derived therapies increases, demand is rising in these regions. Companies are expanding their distribution networks and forging partnerships to tap into these growing markets, driving further market penetration and revenue generation.
• Technological Advancements in Plasma Processing: Technological innovations in plasma collection and processing provide further growth opportunities because they have significantly improved efficiency and yield from plasma-derived therapies. Automated collection systems and innovative methods of purification can help the manufacturer meet an increase in demand for these therapies with product quality unaffected. All of these will result in improvement of production capacities as well as savings, therefore enabling plasma-derived therapies to be extended to more patients.
The Plasma-derived Therapies Market has growth opportunities through strategic expansion, innovation, and rising demand in global markets. Such companies can benefit by tapping into these opportunities and strengthening their position in the market and meeting the emerging healthcare needs of patients across the globe.
Plasma-Derived Therapies Market Driver and Challenges
The Plasma-derived Therapies Market is shaped by several key drivers and challenges. Technological advancements, economic factors, and regulatory changes play a major role in driving market growth, while challenges such as supply chain issues and regulatory hurdles present ongoing obstacles.
The factors responsible for driving the plasma-derived therapies market include:
1. Technological Advancements in Plasma Processing: Technological advancements are the major growth drivers in the Plasma-derived Therapies Market. Improvements in plasma collection and purification processes increase the efficiency, safety, and yield of plasma-derived products. Automation in these processes is reducing costs and improving the scalability of production, allowing manufacturers to meet the growing global demand for plasma therapies.
2. Growing Demand for Immunoglobulin and Clotting Factor Therapies: The increasing prevalence of immune disorders and bleeding disorders will trigger the demand for immunoglobulins and clotting factor therapies. As more and more of the worldÄX%$%Xs population ages, the incidence of these diseases will increase, and hence the market for plasma-derived products will expand substantially. What is fueling the demand of this is with advanced formulations and better outcomes of patients in plasma therapy.
3. Regulatory Support and Market Approvals: Regulatory bodies such as the FDA and EMA are providing clearer and more supportive guidelines for the development of plasma-derived therapies. Streamlined approval processes and new regulatory frameworks are making it easier for companies to bring innovative plasma-based treatments to market, accelerating growth in the sector.
4. Increasing Healthcare Access in Emerging Markets: Healthcare access is expanding rapidly in emerging markets, where the demand for plasma-derived therapies is increasing. Improvements in healthcare infrastructure, patient education, and access to life-saving treatments are contributing to market growth in regions such as Asia-Pacific, Latin America, and Africa.
5. Collaborations and Partnerships: Strategic collaborations between pharmaceutical companies, research institutions, and plasma collection centers are driving innovation in the Plasma-derived Therapies Market. These partnerships are helping to overcome challenges related to plasma supply, manufacturing capabilities, and regulatory approval, fueling market expansion.
Challenges in the plasma-derived therapies market are:
1. Plasma Supply Shortages: Plasma supply shortages remain a significant challenge for the Plasma-derived Therapies Market. The global demand for plasma-derived products often outpaces the supply of high-quality plasma, leading to supply chain bottlenecks. Efforts to increase plasma donation rates and expand collection centers are critical to overcoming this challenge.
2. Regulatory Complexity: Despite efforts to harmonize regulations, the global regulatory landscape for plasma-derived therapies remains complex. Navigating different regulatory requirements across regions can delay product approval and complicate market entry for manufacturers. Standardizing regulations would help streamline the process and reduce barriers to market expansion.
3. High Treatment Costs: The high cost of plasma-derived therapies presents an economic challenge for both patients and healthcare systems. The cost of manufacturing, along with logistical and regulatory expenses, contributes to the high prices of plasma products. Efforts to reduce production costs and improve access to treatment are critical for ensuring affordability.
The major drivers and challenges in the Plasma-derived Therapies Market are shaping the future of this industry. While advancements in technology, rising demand, and regulatory support offer significant growth opportunities, challenges related to plasma supply, regulatory complexity, and treatment costs remain hurdles that need to be addressed to ensure sustainable market growth.
List of Plasma-Derived Therapies Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies plasma-derived therapies companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the plasma-derived therapies companies profiled in this report include-
• Takeda
• CSL
• Grifols
• Octapharma
• Kedrion
• LFB Group
• Biotest
• BPL
• Raas
• CBPO
Plasma-Derived Therapies Market by Segment
The study includes a forecast for the global plasma-derived therapies market by type, application, and region.
Plasma-Derived Therapies Market by Type [Value from 2019 to 2031]:
• Immune Globulin
• Coagulation Factor
• Albumin
• Other
Plasma-Derived Therapies Market by Application [Value from 2019 to 2031]:
• Hospital
• Retail Pharmacy
• Other
Plasma-Derived Therapies Market by Region [Value from 2019 to 2031]:
• North America
• Europe
• Asia Pacific
• The Rest of the World
Country Wise Outlook for the Plasma-Derived Therapies Market
Advancements have been significant in the Plasma-derived Therapies Market lately. Several technological innovations, added demand for treatments, and appropriate regulatory frameworks have collectively contributed to this advance. Plasma-derived therapies are critical treatment options for many medical conditions, including immune deficiencies, hemophilia, and chronic liver diseases. These consist of immunoglobulins, clotting factors, and albumin. In the United States, China, Germany, India, and Japan, market development in research, production, and regulatory practices are contributing to growth in the market and patient outcomes. Such advancements are reshaping the global healthcare landscape.
• United States: In the United States, the Plasma-derived Therapies Market remains the leader globally in terms of production and innovation. Improvements in plasma collection technologies and development of more efficient purification methods are also among the major breakthroughs. Additionally, regulatory policies have eased their way into more friendly territory, and clearer FDA guidelines to manufacturers provide much relief. More investments in research in plasma-derived products have helped increase therapeutic application in fields like immunology and rare diseases. These initiatives are contributing toward improved availability of required therapies to patients across the country.
• China: China is gaining momentum in the Plasma-derived Therapies Market with both domestic innovations and international collaborations. The country has heavily invested in plasma collection centers and is expanding its production capabilities for immunoglobulins and clotting factor therapies. The Chinese government has launched beneficial policies and regulatory reforms to foster the plasma industryÄX%$%Xs growth. It is doing this by boosting domestic plasma supply, thus cutting dependence on imports. All these factors combined with increasing demand for blood plasma-derived treatments, position China as an important player in the market, especially in the Asia-Pacific region.
• Germany: Germany is one of the prominent countries in the Plasma-derived Therapies Market in Europe. The country has experienced significant growth in its plasma collection infrastructure and advanced research in immunoglobulin therapies. GermanyÄX%$%Xs regulatory framework, under the European Medicines Agency (EMA), supports the development of new plasma-derived treatments while ensuring safety and efficacy. Innovations in the processing of plasma and its derivatives, such as improved purification techniques, have enhanced product quality. Additionally, Germany is a center for clinical trials that support the worldwide development of plasma-based therapies for different medical conditions, such as autoimmune diseases and bleeding disorders.
• India: The Plasma-derived Therapies Market in India is growing at a very fast pace, driven by the increasing patient population and rising awareness about healthcare. The country is working to strengthen its plasma collection infrastructure and address regulatory issues regarding plasma-derived products. India is also set to create a more effective plasma donation network to increase the contribution of plasma donation, which is expected to reduce the deficiency for immunoglobulins and other plasma-derived therapy. Even with the problems from supply and the regulatory framework in place, it is still hoped that India is going to continue to become increasingly important to the global plasma-derived therapies market due to its development in the health sector.
• Japan: Japan has been quite advanced in the Plasma-derived Therapies Market, especially in the immunoglobulin and clotting factor therapies. The country has strong regulatory mechanisms that ensure safety and efficacy in plasma-derived products. It is also investing significantly in research for new applications of plasma-derived therapies, especially in immune-related disorders and chronic diseases. The surging demand for plasma products in the healthcare sector gives rise to enhanced plasma donation drives and new plasma collection centers. Japan is setting a benchmark through manufacturing and quality control, making it a leading player in Asia.
Features of the Global Plasma-Derived Therapies Market
Market Size Estimates: Plasma-derived therapies market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
Segmentation Analysis: Plasma-derived therapies market size by type, application, and region in terms of value ($B).
Regional Analysis: Plasma-derived therapies market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the plasma-derived therapies market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the plasma-derived therapies market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q1. What is the growth forecast for plasma-derived therapies market?
Answer: The global plasma-derived therapies market is expected to grow with a CAGR of 6.5% from 2025 to 2031.
Q2. What are the major drivers influencing the growth of the plasma-derived therapies market?
Answer: The major drivers for this market are rising prevalence of chronic diseases, advancements in plasma collection and processing technologies, and growing awareness and acceptance of plasma-based treatments.
Q3. What are the major segments for plasma-derived therapies market?
Answer: The future of the plasma-derived therapies market looks promising with opportunities in the hospital and retail pharmacy markets.
Q4. Who are the key plasma-derived therapies market companies?
Answer: Some of the key plasma-derived therapies companies are as follows:
• Takeda
• CSL
• Grifols
• Octapharma
• Kedrion
• LFB Group
• Biotest
• BPL
• Raas
• CBPO
Q5. Which plasma-derived therapies market segment will be the largest in future?
Answer: Lucintel forecasts that, within the type category, immune globulin is expected to witness the highest growth over the forecast period due to its widespread use in treating immune deficiencies.
Q6. In plasma-derived therapies market, which region is expected to be the largest in next 5 years?
Answer: In terms of region, North America is expected to witness the highest growth over the forecast period due to high demand for plasma therapies.
Q7. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the plasma-derived therapies market by type (immune globulin, coagulation factor, albumin, and other), application (hospital, retail pharmacy, and other), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Plasma-Derived Therapies Market, Plasma-Derived Therapies Market Size, Plasma-Derived Therapies Market Growth, Plasma-Derived Therapies Market Analysis, Plasma-Derived Therapies Market Report, Plasma-Derived Therapies Market Share, Plasma-Derived Therapies Market Trends, Plasma-Derived Therapies Market Forecast, Plasma-Derived Therapies Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.